Detection of the Fatty Acid Metabolism‐Linked Genes in Lung Adenocarcinoma as Biomarkers for Clinical Prognosis and Immunotherapeutic Targets
The Clinical Respiratory Journal · 2024
DOI: 10.1111/crj.70013 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2024. Verfasst von Jingwei Shi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province, Ch…. Hauptthemen laut MEDLINE: Lung Neoplasms, Biomarkers, Tumor, Fatty Acids, Adenocarcinoma of Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Project of Nanjing Medical Science and Technology Program.
Abstract (Originalsprache)
Background
Lung cancer, on a global scale, leads to the most common cases of cancer mortalities. Novel therapeutic approaches are urgently needed to disrupt this lethal disease. The rapid development of tumor immunology combining breakthroughs involving fatty acid metabolism brings possibilities. Directing fatty acid metabolism is supposed to help discover potential prognostic biomarkers and treatment targets for lung cancer.
Methods
Through searching the GSE140797 dataset, we identified genes related to fatty acid metabolism as well as fatty acid metabolism‐related differentially expressed genes (DEGs). We applied various methods to ascertain the independent prognostic value of the DEGs. The methods we utilized entail prognostic analysis, differential expression analysis, as well as univariate and multivariate Cox regression analyses. The lasso Cox regression model was utilized in examining how DEGs correlate with the immune score, immune checkpoint, ferroptosis, methylation, and OCLR score. The expression levels of ACAT1 and ACSL3 in tissues derived from normal lung and lung adenocarcinoma (LUAD) tissues were compared by qRT‐PCR.
Results
In this study, ACSL3 and ACAT1 were identified as fatty acid metabolism‐related genes utilizing independent prognostic value and as a result, the risk prognostic model was built using these factors. qRT‐PCR results implied that ACSL3 and ACAT1 expressions were upregulated and downregulated, correspondingly in tumor tissues. Additional evaluations suggested that ACSL3 and ACAT1 were affirmed to be remarkably correlated with the immune score, methylation, immune checkpoint, OCLR score, and ferroptosis.
Conclusions
ACSL3 and ACAT1 were effective prognostic biomarkers and potential immunotherapeutic targets in LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province, China.
- Department of Cardiovascular and Thoracic Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Nanjing University, Nanjing, Jiangsu Province, China.
- Department of Thoracic Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu Province, China.
ORCID-Profile: Kangle Zhu, Zhengcheng Liu
Förderung
- Key Project of Nanjing Medical Science and Technology Program
Zitieren
APA
Shi, J., Yang, R., Jiang, X., Zhu, K., & Liu, Z. (2024). Detection of the Fatty Acid Metabolism‐Linked Genes in Lung Adenocarcinoma as Biomarkers for Clinical Prognosis and Immunotherapeutic Targets. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70013
Vancouver
Shi J, Yang R, Jiang X, Zhu K, Liu Z. Detection of the Fatty Acid Metabolism‐Linked Genes in Lung Adenocarcinoma as Biomarkers for Clinical Prognosis and Immunotherapeutic Targets. The Clinical Respiratory Journal. 2024. doi:10.1111/crj.70013
BibTeX
@article{Shi2024,
author = {Shi, Jingwei and Yang, Rusong and Jiang, Xinyi and Zhu, Kangle and Liu, Zhengcheng},
title = {Detection of the Fatty Acid Metabolism‐Linked Genes in Lung Adenocarcinoma as Biomarkers for Clinical Prognosis and Immunotherapeutic Targets},
journal = {The Clinical Respiratory Journal},
year = {2024},
doi = {10.1111/crj.70013}
}
EUVIMED